Alyeska Investment Group’s Cytek Biosciences CTKB Stock Holding History

Alyeska Investment Group’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100,000	Closed	-$649K	–	539
2024 Q4	$649K	Hold	100,000	–	–	﹤0.01%	509
2024 Q3	$554K	Hold	100,000	–	–	﹤0.01%	484
2024 Q2	$558K	Hold	100,000	–	–	﹤0.01%	497
2024 Q1	$671K	Hold	100,000	–	–	﹤0.01%	424
2023 Q4	$912K	Hold	100,000	–	–	0.01%	410
2023 Q3	$552K	Hold	100,000	–	–	﹤0.01%	445
2023 Q2	$854K	Hold	100,000	–	–	0.01%	463
2023 Q1	$919K	Hold	100,000	–	–	0.01%	393
2022 Q4	$1.02M	Hold	100,000	–	–	0.01%	346
2022 Q3	$1.47M	Hold	100,000	–	–	0.02%	336
2022 Q2	$1.07M	Hold	100,000	–	–	0.01%	460
2022 Q1	$1.08M	Buy	+100,000	New	+$1.35M	0.01%	489
2021 Q4	–	Sell	-75,000	Closed	-$1.61M	–	630
2021 Q3	$1.61M	Buy	+75,000	New	+$1.76M	0.02%	531

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alyeska Investment Group's CTKB Position: Q1 2025 in Review

Alyeska Investment Group sold out of Cytek Biosciences (CTKB) in Q1 2025, closing a stake of 100,000 shares — an estimated $649K sold.

Alyeska Investment Group first reported a position in CTKB in Q3 2021 and held it in 13 quarters. The position peaked at $1.61M in Q3 2021. 160 funds tracked by Wall St. Rank hold CTKB as of Q1 2025.

Alyeska Investment Group reported no remaining Cytek Biosciences position as of Q1 2025 after selling out during the quarter.
Alyeska Investment Group sold 100,000 Cytek Biosciences shares in Q1 2025, an estimated $649K.
Alyeska Investment Group first reported a position in Cytek Biosciences in Q3 2021 and held it in 13 quarters.
Alyeska Investment Group's Cytek Biosciences position peaked at $1.61M in Q3 2021.
160 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2025.

Based on Alyeska Investment Group's 13F filing for Q1 2025, filed 15 May 2025.